FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. PMID 40789106 · J Clin Oncol · 2025-Nov-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 1 Figure · 2 Panel · risk visible |
| Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy. PMID 40632972 · J Clin Oncol · 2025-Nov-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. PMID 40239134 · J Clin Oncol · 2025-Nov-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol. PMID 41213710 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trial. PMID 41213708 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparison of ciprofol versus propofol on gastrointestinal motility in patients undergoing laparoscopic radical resection for colorectal cancer: study protocol for a randomised controlled trial. PMID 41213705 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Addition of baseline histology and fecal calprotectin does not reduce placebo rates in ulcerative colitis clinical trials: post-hoc analysis of patient-level data. PMID 41208025 · J Crohns Colitis · 2025-Nov-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial. PMID 41207813 · Eur Urol Oncol · 2025-Nov-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study. PMID 41205003 · J Neurol · 2025-Nov-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. PMID 41125110 · Lancet · 2025-Nov-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. PMID 41115436 · Lancet · 2025-Nov-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Gastric Cancer with Peritoneal Metastases: Why Patient-Reported Outcomes Matter in Clinical Trials. PMID 41203914 · J Gastrointest Cancer · 2025-Nov-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Protocol for NAC Attack, a phase-3, multicenter randomized, parallel, double masked, placebo controlled trial evaluating the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa. PMID 41282901 · medRxiv · 2025-Nov-06 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of Metformin on Cancer Survival Among Men Diagnosed with Advanced Prostate Cancer Treated with Androgen-Deprivation Therapy: Emulating a Target Trial. PMID 41228370 · Cancers (Basel) · 2025-Nov-06 The record describes an observational study (target trial emulation) using SEER-Medicare data, not a randomized clinical trial. While it is an oncology study in humans with a drug intervention (metformin) and a time-to-event endpoint (mortality), it fails the core requirement of being a report of a randomized trial (Phase III/IIIb or Phase II/III). The publication type is 'Journal Article', but the content is an observational analysis, not a report of a pre-specified randomized trial protocol or its results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Good School Toolkit-Secondary to prevent violence against students: a pilot cluster randomised controlled trial. PMID 41199238 · BMC Public Health · 2025-Nov-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Opioid-free anesthesia with quadratus lumborum block and Esketamine enhances postoperative recovery in laparoscopic colon cancer surgery: A randomized controlled trial. PMID 41198736 · Sci Rep · 2025-Nov-06 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Anxiety, repetitive and restricted behaviors and interests, and social communication in autistic adults: an exploratory analysis of a phase 3, randomized clinical trial. PMID 41198718 · Sci Rep · 2025-Nov-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Valganciclovir for cytomegalovirus viraemia in advanced HIV disease: a phase 2b randomized placebo-controlled trial of valganciclovir for cytomegalovirus viraemia in adults and adolescents with advanced HIV disease. PMID 41194665 · Philos Trans R Soc Lond B Biol Sci · 2025-Nov-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. PMID 41191940 · N Engl J Med · 2025-Nov-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer. PMID 41191939 · N Engl J Med · 2025-Nov-06 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 2 Panel · risk unclear |
| Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. PMID 40960239 · N Engl J Med · 2025-Nov-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. PMID 40737595 · Blood · 2025-Nov-06 The study is an oncology RCT reporting long-term overall survival results with a drug intervention. However, the phase is not explicitly stated in the provided metadata (e.g., publication type does not include 'Phase III' or similar), and the trial design compares two complex strategies rather than a direct drug-vs-placebo/standard-of-care comparison. The phase criterion cannot be definitively established as met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of the novel simultaneous biplane versus in-plane imaging technique in ultrasound-guided biopsy: a prospective randomized multi-operator cross-over phantom study. PMID 40351114 · Diagn Interv Radiol · 2025-Nov-06 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effect of perioperative lidocaine application on inflammatory factors, immune function, and quality of early postoperative recovery in patients undergoing video-assisted thoracoscopic surgery: a randomized controlled trial. PMID 41194239 · Eur J Med Res · 2025-Nov-05 The record describes a randomized, drug-intervention trial in human lung cancer patients, but it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). The reported outcomes are biomarkers and quality-of-recovery measures. The trial phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. PMID 41193417 · Nat Commun · 2025-Nov-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials. PMID 41190692 · J Psychoactive Drugs · 2025-Nov-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Metronidazole exposure-response and safety in infants. PMID 40970766 · Antimicrob Agents Chemother · 2025-Nov-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir. PMID 40965470 · Antimicrob Agents Chemother · 2025-Nov-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Characterisation of patients with antifibrotic-treated non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis: a retrospective real-life study. PMID 41248325 · BMJ Open · 2025-Nov-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy. PMID 41188218 · Nat Commun · 2025-Nov-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. PMID 41147407 · J Am Heart Assoc · 2025-Nov-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. PMID 41128134 · J Am Heart Assoc · 2025-Nov-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial. PMID 40982270 · JAMA · 2025-Nov-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. PMID 40839760 · Eur Heart J Cardiovasc Pharmacother · 2025-Nov-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials. PMID 41222935 · JAMA Netw Open · 2025-Nov-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Acute Kidney Injury and Neurodevelopmental Outcomes in Extremely Premature Neonates: A Secondary Analysis of a Randomized Clinical Trial. PMID 41222934 · JAMA Netw Open · 2025-Nov-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| E-Health Intervention for Fear of Cancer Recurrence: A Randomized Clinical Trial. PMID 41217757 · JAMA Netw Open · 2025-Nov-03 The study is a randomized clinical trial in oncology (colorectal cancer survivors) with primary results, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified, not meeting definitive phase criteria), does not involve a drug intervention (e-health/psychological intervention), and does not use a time-to-event efficacy endpoint (primary outcome is change in a patient-reported outcome score). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis. PMID 41206886 · JAMA Netw Open · 2025-Nov-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial. PMID 41196599 · JAMA Netw Open · 2025-Nov-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO). PMID 41184224 · Nat Commun · 2025-Nov-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia. PMID 40905823 · Cancer Epidemiol Biomarkers Prev · 2025-Nov-03 While the record describes a Phase III randomized trial with drug intervention in human oncology (childhood ALL), it does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The study's focus is on biomarkers of oxidative stress and neurodegeneration (CSF 8-hydroxydeoxyguanosine and total tau) as potential predictors of neurocognitive impairment, not survival or progression-free outcomes. Therefore, it does not meet the eligibility criteria for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer. PMID 40864501 · Clin Cancer Res · 2025-Nov-03 The record describes a definitive randomized, controlled Phase III trial (TROPION-Breast01) with a drug intervention and time-to-event efficacy endpoints (PFS, OS) that resulted in an FDA approval. The full eligibility criteria are explicitly established in the abstract and metadata. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | no_km 0 Figure · 0 Panel · risk not_applicable |
| Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. PMID 40853871 · Clin Cancer Res · 2025-Nov-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial. PMID 40810606 · Cancer Epidemiol Biomarkers Prev · 2025-Nov-03 The study is a randomized, oncology, human trial, but it is excluded because it does not test a drug intervention (it tests screening modalities) and its primary endpoint is not a time-to-event efficacy outcome (OS, PFS, etc.) suitable for Kaplan-Meier analysis. The analysis models preclinical detectable phase duration, not survival or progression. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis. PMID 41177553 · BMJ Open Ophthalmol · 2025-Nov-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| CDK4/6 Inhibitors Plus Endocrine Therapy in Early-Stage HR+/HER2- Breast Cancer: Updated Meta-Analysis of Phase III Trials. PMID 41228331 · Cancers (Basel) · 2025-Nov-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of Intravesical Bacillus Calmette-Guérin Therapy Following Transurethral En Bloc Resection of Bladder Tumour: Post Hoc Analysis of a Randomised, Multicentre, Phase 3 Trial. PMID 41177716 · Eur Urol Oncol · 2025-Nov-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial. PMID 41125112 · Lancet · 2025-Nov-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. PMID 41125109 · Lancet · 2025-Nov-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer. PMID 41123992 · Cancer Res Commun · 2025-Nov-01 The record describes a preclinical/mechanistic study of xevinapant's effects on the tumor microenvironment, referencing the Phase III TrilynX trial's lack of clinical benefit, but does not report the trial's clinical efficacy results (OS, PFS, etc.) or include KM/HR data. It is not an original clinical result report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |